Bing

SEARCH HISTORY

Amgen (NASDAQ:AMGN)‘s stock had its “market perform” rating reaffirmed by equities research analysts at BMO Capital Markets in a research note issued to investors on Saturday. They currently have a $12.00 price objective on the stock, down from …
Mideast Times · 5/16/2015
Actavis is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include Gilead Sciences Inc. GILD, Amgen, Inc. AMGN and Acorda Therapeutics, Inc. ACOR. While Gilead is a Zacks Rank #1 (Strong Buy) stock, Amgen and …
Yahoo News · 8 hours ago
Amgen (NASDAQ: AMGN ) , for example, lacked this internal growth engine ... any intermediary concerns about patent exclusivity losses. Unsurprisingly, its stock has tripled in price since 2011. Secondly, a biotech …
The Motley Fool · BySean Williams · 1 day ago
biotech
More from Bing News
Actavis is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include Gilead Sciences Inc. (GILD - Analyst Report), Amgen, Inc. (AMGN - Analyst Report) and Acorda Therapeutics, Inc. (ACOR - Analyst Report). While Gilead …
ZACKS · 15 hours ago
The company said inventory also grew and it continued to buy back stock. AstraZeneca (AZN) shares are lower in early trading. Amgen (AMGN) said late Friday it's ending its partnership with AstraZeneca to develop a psoriasis drug after some patients who ...
Yahoo Finance · 17 hours ago
Investor focus will remain on the outcome of the FDA advisory panel meetings. Amgen is a Zacks Rank #2 (Buy) stock. A better-ranked stock in the biotech sector is Gilead Sciences Inc. GILD, a Zacks Rank #1 (Strong Buy) company. Want the latest ...
NASDAQ · 1 day ago
EU Approval
Amgen Inc. (NASDAQ:AMGN) stock still has plenty of life, despite the market’s lukewarm take on the biotech giant in 2015. Although the market reacted negatively to AMGN’s prospects on its product line and future earnings, a second look tells a ...
Investor Place · 2/20/2015
Amgen (O:AMGN), its partner on the project, announced late on Friday it was ending a collaboration to develop brodalumab after suicidal thoughts were observed in patients taking the medicine. Shares in AstraZeneca …
investing.com · 21 hours ago
After Third Point, Samuel Isaly‘s healthcare fund Orbimed Advisors is the second-largest shareholder of Amgen, Inc. (NASDAQ:AMGN) within our database, owning 3.05 million shares. Third Point’s second-largest stock pick, Actavis plc (NYSE:ACT ...
INSIDER MONKEY · 5/21/2015
NEW YORK (TheStreet) -- Amgen (AMGN - Get Report) shares are down 1.37% to $156.72 in trading on Wednesday following the release of the company's fourth quarter earnings after the closing bell yesteray. The world's largest biotech company reported …
The Street · 1/28/2015